New Two-Pronged attack on advanced cancers enters testing
NCT ID NCT05229497
Summary
This study is testing a combination of two new drugs, AK112 and AK117, for people with advanced cancers that have spread or returned. The main goals are to see if the treatment is safe and if it can shrink or control tumors. It is open to adults with certain types of head and neck cancers who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.